FINDINGS
Through gene therapy, researchers engineered blood-forming stem cells (hematopoietic stem/progenitor cells, or HSPCs) to carry chimeric antigen receptor (CAR) genes to make cells that can detect and destroy HIV-infected cells. These engineered cells not only destroyed the infected cells, they persisted for more than two years, suggesting the potential to create long-term immunity from the virus that causes AIDS.
BACKGROUND
Antiviral drugs can suppress the amount of HIV in the body to nearly undetectable levels, but only an effective immune response can eradicate the virus. Researchers have been seeking a way to improve the body’s ability to combat the virus by engineering blood-forming stem cells to specifically target and kill HIV-infected cells for the life of the individual. Although chimeric antigen receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer – and show promise in treating HIV-1 infection – the therapy may not impart long-lasting immunity. Researchers, physicians and patients need T cell-based products that can respond to malignant or infected cells that may reappear months or years after treatment.
METHOD
Because HIV uses CD4 to infect cells, the researchers used a CAR molecule that hijacks the essential interaction between HIV and the cell surface molecule CD4 to make stem cell-derived T-cells target infected cells. When the CD4 on the CAR molecule binds to HIV, other regions of the CAR molecule signal the cell to become activated and kill the HIV infected cell. The researchers found that, in test animals, modification of the blood-forming stem cells resulted in more than two years of stable production of CAR-expressing cells without any adverse effects. In addition, these cells were widely distributed throughout the lymphoid tissues and gastrointestinal tract, which are major anatomic sites for HIV replication and persistence in infected people. Most important, engineered CAR T-cells showed efficacy in attacking and killing HIV-infected cells.
IMPACT
These findings are the first to show that blood-forming stem cells can be modified with a CAR therapy that can safely engraft in the bone marrow, mature and become functional immune cells throughout the body. This could lead to the development of an approach allowing for safe, lifelong immunity to HIV. Such an approach is likely to work best when performed in combination with other treatment strategies, such as antiretroviral therapy. Researchers hope that this type of therapy could reduce infected individuals’ dependence on antiviral medications, lower the cost of therapy, and permit the possible eradication of HIV from its hiding places in the body. The approach also has potential against other infections or malignancies.
Learn more: Gene Therapy Using CAR T-Cells Could Provide Long-Term Protection Against HIV
The Latest on: HIV gene therapy
[google_news title=”” keyword=”HIV gene therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- GPS-like system shows promise as HIV vaccine strategy to elicit critical antibodieson May 9, 2024 at 3:38 pm
A team has developed a vaccine approach that works like a GPS, guiding the immune system through the specific steps to make broadly neutralizing antibodies against HIV.
- Q&A: Scientist partners with colleagues around the globe to make gene therapies more effective and widely availableon May 9, 2024 at 2:00 pm
Fred Hutch Cancer Center scientist Jennifer E. Adair, Ph.D., is on a mission to foster worldwide collaboration on potentially curative gene therapies.
- Q&A with Jennifer Adair, researcher on a mission to increase global access to gene therapieson May 8, 2024 at 5:00 pm
with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income ...
- Controversial scientist says he’ll use gene editing to end HIV & Alzheimer’son May 8, 2024 at 3:18 pm
Right now, U.S. law and universal medical ethics state that gene editing should only be used on laboratory animals, in order to test whether the technology might be safe for humans. But if He is ...
- NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIVon May 8, 2024 at 3:00 am
Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.
- Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024on May 7, 2024 at 4:22 am
About Lenmeldy Lenmeldy™ (atidarsagene autotemcel), formerly known as OTL-200, is the only approved therapy in the U.S. for the treatment of children with pre-symptomatic late infantile (PSLI), ...
- How HIV drugs have changed over the decadeson May 7, 2024 at 2:01 am
From one big pill that only prolonged lives a few months, through the 20 pills a day years to modern combination therapies, treating HIV is a science success story ...
- HIV and AIDS Newson May 6, 2024 at 4:59 pm
Children Surpass a Year of HIV Remission After Treatment Pause Mar. 7, 2024 — Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART ...
- Washington University in St. Louis Receives $6.2 Million Grant to Advance Gene Therapy for HIVon April 23, 2024 at 8:20 pm
HIV infections can be controlled with medication, but such therapy must continue throughout patients’ lives because no strategy exists to eliminate the virus from the body or control the infection ...
- Researchers receive NIH grant to help develop gene therapy for HIVon April 17, 2024 at 5:00 pm
We have brought together a great team with expertise in HIV, gene therapy, and animal models of infection to work toward this goal." David T. Curiel, MD, PhD, the Distinguished Professor of ...
via Google News and Bing News